抗乙型肝炎病毒药物在乙肝母婴阻断的治疗进展
摘要
的阻断一直是降低疾病负荷的重要措施。目前可用于HBV母婴阻断的抗病毒药物有替比夫定、拉米夫定、富马酸替
诺福韦二吡呋酯，近年来，随着更多高质量证据的支持，富马酸丙酚替诺福韦亦开始用于HBV的母婴阻断。本文就
上述抗病毒药物在阻断HBV母婴传播中的用药指征、有效性、安全性、药物选择、用药时机、停药时机进行总结，
以期对临床实践中HBV母婴阻断抗病毒药物的合理应用提供帮助。
关键词
全文:
PDF参考
[1]Yeo YH, Nguyen MH: Review article: current gaps
and opportunities in HBV prevention, testing and linkage to
care in the United States-a call for action. Aliment Pharmacol
Ther 2021, 53(1):63-78.
[2]尤红，王福生，李太生，孙亚朦，徐小元，贾继
东，南月敏，王贵强，侯金林，魏来et al：慢性乙型肝
炎防治指南（2022年版）.实用肝脏病杂志，2023，26
（03）：457-478.
[3]Liu J, Liang W, Jing W, Liu M: Countdown to 2030:
eliminating hepatitis B disease, China. Bull World Health
Organ 2019, 97(3):230-238.
[4]Global prevalence, treatment, and prevention of
hepatitis B virus infection in 2016: a modelling study. Lancet
Gastroenterol Hepatol 2018, 3(6):383-403.
[5]Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X:
Telbivudine or lamivudine use in late pregnancy safely reduces
perinatal transmission of hepatitis B virus in real-life practice.
Hepatology 2014, 60(2):468-476.
[6]Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang
Y, Zhang H, Zou H, Zhu B, Zhao W et al: Tenofovir to
Prevent Hepatitis B Transmission in Mothers with High Viral
Load. N Engl J Med 2016, 374(24):2324-2334.
[7]阻断乙型肝炎病毒母婴传播临床管理流程（2021
年）.临床肝胆病杂志，2021，37（03）：527-531.
[8]EASL 2017 Clinical Practice Guidelines on the
management of hepatitis B virus infection. J Hepatol 2017,
67(2):370-398.
[9]Terrault NA, Lok ASF, McMahon BJ, Chang KM,
Hwang JP, Jonas MM, Brown RS, Jr., Bzowej NH, Wong
JB: Update on prevention, diagnosis, and treatment of chronic
hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology
2018, 67(4):1560-1599.
[10]Kumar M, Abbas Z, Azami M, Belopolskaya M,
Dokmeci AK, Ghazinyan H, Jia J, Jindal A, Lee HC, Lei W
et al: Asian Pacific association for the study of liver (APASL)
guidelines: hepatitis B virus in pregnancy. Hepatol Int 2022,
16(2):211-253.
[11]中华医学会感染病学分会，GRADE中国中心：
中国乙型肝炎病毒母婴传播防治指南（2019年版）.中华
传染病杂志，2019，37（7）：388-396.
[12]周乙华，杨慧霞，胡娅莉，刘兴会：乙型肝炎
病毒母婴传播预防临床指南（2020）.临床肝胆病杂志，
2020，36（07）：1474-1481.
[13]WHO Guidelines Approved by the Guidelines
Review Committee. In: Prevention of Mother-toChild Transmission of Hepatitis B Virus: Guidelines on
Antiviral Prophylaxis in Pregnancy. Geneva: World Health
Organization
[14]Funk AL, Lu Y, Yoshida K, Zhao T, Boucheron P,
van Holten J, Chou R, Bulterys M, Shimakawa Y: Efficacy
and safety of antiviral prophylaxis during pregnancy to
prevent mother-to-child transmission of hepatitis B virus: a
systematic review and meta-analysis. Lancet Infect Dis 2021,
21(1):70-84.
[15]李冀宏：拉米夫定和乙型肝炎疫苗及免疫球蛋
白三者联合阻断乙型肝炎母婴传播的临床研究.中国全科
医学，2017，20（S1）：128-130.
[16]He T, Bai Y, Cai H, Ou X, Liu M, Yi W, Jia J:
Safety and efficacy of lamivudine or telbivudine started in
early pregnancy for mothers with active chronic hepatitis B.
Hepatol Int 2018, 12(2):118-125.
[17]Han GR, Cao MK, Zhao W, Jiang HX, Wang CM,
Bai SF, Yue X, Wang GJ, Tang X, Fang ZX: A prospective
and open-label study for the efficacy and safety of telbivudine
in pregnancy for the prevention of perinatal transmission of
hepatitis B virus infection. J Hepatol 2011, 55(6):1215-1221.
[18]Wang M, Bian Q, Zhu Y, Pang Q, Chang L,
Li R, Tiongson BC, Zhang H, Pan CQ: Real-world
study of tenofovir disoproxil fumarate to prevent hepatitis
B transmission in mothers with high viral load. Aliment
Pharmacol Ther 2019, 49(2):211-217.
[19]Lin Y, Liu Y, Ding G, Touqui L, Wang W, Xu N,
Liu K, Zhang L, Chen D, Wu Y et al: Efficacy of tenofovir
in preventing perinatal transmission of HBV infection in
pregnant women with high viral loads. Sci Rep 2018,
8(1):15514.
[20]Lim YS, Lee YS, Gwak GY, Byun KS, Kim YJ,
Choi J, An J, Lee HC, Yoo BC, Kwon SY: Monotherapy
with tenofovir disoproxil fumarate for multiple drugresistant chronic hepatitis B: 3-year trial. Hepatology 2017,
66(3):772-783.
[21]Marcellin P, Wong DK, Sievert W, Buggisch P,
Petersen J, Flisiak R, Manns M, Kaita K, Krastev Z, Lee SS
et al: Ten-year efficacy and safety of tenofovir disoproxil
fumarate treatment for chronic hepatitis B virus infection.
Liver Int 2019, 39(10):1868-1875.
[22]Chan HL, Fung S, Seto WK, Chuang WL, Chen
CY, Kim HJ, Hui AJ, Janssen HL, Chowdhury A, Tsang
TY et al: Tenofovir alafenamide versus tenofovir disoproxil
fumarate for the treatment of HBeAg-positive chronic
hepatitis B virus infection: a randomised, double-blind, phase
3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016,
1(3):185-195.
[23]Kayes T, Crane H, Symonds A, Dumond J, Cottrell
M, Di Girolamo J, Manandhar S, Lim TH, Gane E, Kashuba
A et al: Plasma and breast milk pharmacokinetics of tenofovir
alafenamide in mothers with chronic hepatitis B infection.
Aliment Pharmacol Ther 2022, 56(3):510-518.
[24]Abdul Basit S, Dawood A, Ryan J, Gish R: Tenofovir
alafenamide for the treatment of chronic hepatitis B virus
infection. Expert Rev Clin Pharmacol 2017, 10(7):707-716.
[25]Li B, Liu Z, Liu X, Liu D, Duan M, Gu Y, Liu
Q, Ma Q, Wei Y, Wang Y: Efficacy and safety of tenofovir
disoproxil fumarate and tenofovir alafenamide fumarate in
preventing HBV vertical transmission of high maternal viral
load. Hepatol Int 2021, 15(5):1103-1108.
[26]Pan CQ, Yi W, Liu M, Wan G, Hu YH, Zhou MF:
Lamivudine therapy during the second vs the third trimester
for preventing transmission of chronic hepatitis B. J Viral
Hepat 2017, 24(3):246-252.
[27]Li Z, Duan X, Hu Y, Zhou M, Liu M, Kang K, Cai
H, Yi W, Fu D, Gao X: Efficacy and Safety of Lamivudine or
Telbivudine in Preventing Mother-to-Child Transmission
of Hepatitis B Virus: A Real-World Study. Biomed Res Int
2020, 2020:1374276.
[28]Jiang H, Ye X, Chen C, Zhou G, Han G: Efficacy
and Long-term Safety of Telbivudine Usage During Second
or Third Trimester in Hepatitis B Surface Antigen Positive
Mothers With High Viral Load: A 10-year Prospective Study.
J Clin Gastroenterol 2023, 57(4):423-428.
[29]Yi W, Cao X, Zeng Z, Cao W, Zhang Y, Sun F,
Wang Y, Wan G, Li M, Xie Y: Developmental consequences
of children born from mothers with telbivudine treatment
during late pregnancy: A prospective study with 3-year
follow-up. Virulence 2021, 12(1):1527-1537.
[30]Salvadori N, Fan B, Teeyasoontranon W, NgoGiang-Huong N, Phanomcheong S, Luvira A, Puangsombat
A, Suwannarat A, Srirompotong U, Putiyanun C et al:
Maternal and Infant Bone Mineral Density 1 Year After
Delivery in a Randomized, Controlled Trial of Maternal
Tenofovir Disoproxil Fumarate to Prevent Mother-tochild Transmission of Hepatitis B Virus. Clin Infect Dis 2019,
69(1):144-146.
[31]田文悦，盛秋菊，张翀，窦晓光，丁洋：乙型
肝炎病毒感染免疫耐受期孕妇应用富马酸丙酚替诺福韦
的疗效和安全性研究.中国实用内科杂志，2020，40（06）：
466-470.
[32]Kourtis AP, Wiener J, Wang L, Fan B, Shepherd
JA, Chen L, Liu W, Shepard C, Wang L, Wang A et al:
Tenofovir Disoproxil Fumarate Use during Pregnancy and
Infant Bone Health: the Tenofovir in Pregnancy Pilot Study.
Pediatr Infect Dis J 2018, 37(11):e264-e268.
[33]Lampertico P, Buti M, Fung S, Ahn SH, Chuang
WL, Tak WY, Ramji A, Chen CY, Tam E, Bae H et al:
Switching from tenofovir disoproxil fumarate to tenofovir
alafenamide in virologically suppressed patients with chronic
hepatitis B: a randomised, double-blind, phase 3, multicentre
non-inferiority study. Lancet Gastroenterol Hepatol 2020,
5(5):441-453.
[34]Chan HLY, Buti M, Lim YS, Agarwal K, Marcellin
P, Brunetto M, Chuang WL, Janssen HLA, Fung S, Izumi N
et al: Long-Term Treatment With Tenofovir Alafenamide
for Chronic Hepatitis B Results in High Rates of Viral
Suppression and Favorable Renal and Bone Safety. Am J
Gastroenterol 2024, 119(3):486-496.
[35]Zeng QL, Zhang HX, Zhang JY, Huang S, Li WZ,
Li GM, Pan YJ, Feng YH, Li ZQ, Zhang GF et al: Tenofovir
Alafenamide for Pregnant Chinese Women With Active
Chronic Hepatitis B: A Multicenter Prospective Study. Clin
Gastroenterol Hepatol 2022, 20(12):2826-2837.e2829.
[36]Shen Y, Jia Y, Zhou J, Ji J, Xun P: Bayesian Network
Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B
Drugs. Clin Drug Investig 2019, 39(9):835-846.
[37]Wu Y, Liu J, Feng Y, Fu S, Ji F, Ge L, Yao N, Luo X,
Zhao Y, Chen Y et al: Efficacy and safety of antiviral therapy
for HBV in different trimesters of pregnancy: systematic
review and network meta-analysis. Hepatol Int 2020,
14(2):180-189.
[38]Liu J, Wang J, Jin D, Qi C, Yan T, Cao F, Jin L,
Tian Z, Guo D, Yuan N et al: Hepatic flare after telbivudine
withdrawal and efficacy of postpartum antiviral therapy for
pregnancies with chronic hepatitis B virus. J Gastroenterol
Hepatol 2017, 32(1):177-183.
[39]Wedemeyer H, Schöneweis K, Bogomolov P,
Blank A, Voronkova N, Stepanova T, Sagalova O, Chulanov
V, Osipenko M, Morozov V et al: Safety and efficacy of
bulevirtide in combination with tenofovir disoproxil fumarate
in patients with hepatitis B virus and hepatitis D virus
coinfection (MYR202): a multicentre, randomised, parallelgroup, open-label, phase 2 trial. Lancet Infect Dis 2023,
23(1):117-129.
[40]Asselah T, Loureiro D, Boyer N, Mansouri A:
Targets and future direct-acting antiviral approaches to
achieve hepatitis B virus cure. Lancet Gastroenterol Hepatol
2019, 4(11):883-892.
[41]Yuen MF, Schiefke I, Yoon JH, Ahn SH, Heo J,
Kim JH, Lik Yuen Chan H, Yoon KT, Klinker H, Manns M
et al: RNA Interference Therapy With ARC-520 Results in
Prolonged Hepatitis B Surface Antigen Response in Patients
With Chronic Hepatitis B Infection. Hepatology 2020,
72(1):19-31.
[42]Lee HW, Park JY, Hong T, Park MS, Ahn
SH: Efficacy of Lenvervimab, a Recombinant Human
Immunoglobulin, in Treatment of Chronic Hepatitis B Virus
Infection. Clin Gastroenterol Hepatol 2020, 18(13):3043-
3045.e3041.
Refbacks
- 当前没有refback。
